CoChat

Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes

Open access

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Interleukin (IL)-1 impairs insulin secretion and induces β-cell apoptosis. Pancreatic β-cell IL-1 expression is increased and interleukin-1 receptor antagonist (IL-1Ra) expression reduced in patients with type 2 diabetes. Treatment with recombinant IL-1Ra improves glycemia and β-cell function and reduces inflammatory markers in patients with type 2 diabetes. Here we investigated the durability of these responses. RESEARCH DESIGN AND METHODS: Among 70 ambulatory patients who had type 2 diabetes, A1C >7.5%, and BMI >27 kg/m2 and were randomly assigned to receive 13 weeks of anakinra, a recombinant human IL-1Ra, or placebo, 67 completed treatment and were included in this double-blind 39-week follow-up study. Primary outcome was change in β-cell function after anakinra withdrawal. Analysis was done by intention to treat. RESULTS: Thirty-nine weeks after anakinra withdrawal, the proinsulin-to-insulin (PI/I) ratio but not stimulated C-peptide remained improved (by −0.07 [95% CI −0.14 to −0.02], P = 0.011) compared with values in placebo-treated patients. Interestingly, a subgroup characterized by genetically determined low baseline IL-1Ra serum levels maintained the improved stimulated C-peptide obtained by 13 weeks of IL-1Ra treatment. Reductions in C-reactive protein (−3.2 mg/l [−6.2 to −1.1], P = 0.014) and in IL-6 (−1.4 ng/l [−2.6 to −0.3], P = 0.036) were maintained until the end of study. CONCLUSIONS: IL-1 blockade with anakinra induces improvement of the PI/I ratio and markers of systemic inflammation lasting 39 weeks after treatment withdrawal.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc09-0533

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Enrollment and outcome. Of the 70 patients who underwent randomization, 67 completed 13 weeks of anakinra or placebo treatment and were included in the present 39-week follow-up study. Of the former anakinra- and placebo-treated patients, 33 and 31, respectively, completed the study.
Figure 1 Enrollment and outcome. Of the 70 patients who underwent randomization, 67 completed 13 weeks of anakinra or placebo treatment and were included in the present 39-week follow-up study. Of the former anakinra- and placebo-treated patients, 33 and 31, respectively, completed the study.CC BY-NC-ND · PubMed Central
Figure 2 Change in glycemic and inflammatory markers at study end. Data for PI/I ratio (A), A1C (B), C-reactive protein (C), and IL-6 (D) at baseline and end of study (week 52) in patients treated with anakinra (■) or placebo (□) from baseline until week 13. Data are means ± SEM.
Figure 2 Change in glycemic and inflammatory markers at study end. Data for PI/I ratio (A), A1C (B), C-reactive protein (C), and IL-6 (D) at baseline and end of study (week 52) in patients treated with anakinra (■) or placebo (□) from baseline until week 13. Data are means ± SEM.CC BY-NC-ND · PubMed Central
Figure 3 IL-1Ra serum levels and genotypes; A1C and insulin requirements. A: Serum IL-1Ra levels at baseline and end of study (week 52) in patients with (□, responders) or without (■, nonresponders) any reduction in A1C after 13 weeks of anakinra treatment. B: Allele frequencies of allele 2 and C of the VNTR tandem repeat polymorphism in intron 2 and the SNP tagged by rs4251961, respectively, of the IL1-Ra gene in responders (□) and nonresponders (■) to anakinra treatment. C: A1C at baseline (week 0), and 13, 26, 39, and 52 weeks in responders (□) and nonresponders (▲) to anakinra treatment. D: Daily insulin dose at baseline and end of study (week 52) in responders (□) and nonresponders (■) to anakinra treatment. Data are means ± SEM or frequencies where indicated.
Figure 3 IL-1Ra serum levels and genotypes; A1C and insulin requirements. A: Serum IL-1Ra levels at baseline and end of study (week 52) in patients with (□, responders) or without (■, nonresponders) any reduction in A1C after 13 weeks of anakinra treatment. B: Allele frequencies of allele 2 and C of the VNTR tandem repeat polymorphism in intron 2 and the SNP tagged by rs4251961, respectively, of the IL1-Ra gene in responders (□) and nonresponders (■) to anakinra treatment. C: A1C at baseline (week 0), and 13, 26, 39, and 52 weeks in responders (□) and nonresponders (▲) to anakinra treatment. D: Daily insulin dose at baseline and end of study (week 52) in responders (□) and nonresponders (■) to anakinra treatment. Data are means ± SEM or frequencies where indicated.CC BY-NC-ND · PubMed Central
Figure 4 β-Cell function after anakinra withdrawal. β-Cell function assessed by PI/I (A); and AUC for C-peptide during an oral glucose-tolerance test (B); an intravenous stimulation with glucose, glucagon, and arginine (C); and the oral and intravenous test combined (D) at baseline, anakinra withdrawal (week 13), and end of study (week 52) in patients with (□, responders) or without (■, nonresponders) any reduction in A1C after 13 weeks of anakinra treatment. A: *P = 0.041 vs. nonresponders at week 13, †P = 0.435 vs. responders week 52, ‡P = 0.016 vs. nonresponders week 52, and §P = 0.005 vs. nonresponders week 52. B: *P = 0.006 vs. nonresponders at week 13, †P = 0.750 vs. responders week 52, ‡P = 0.021 vs. nonresponders week 52, and §P = 0.008 vs. nonresponders week 52. C: *P = 0.048 vs. nonresponders at week 13, †P = 0.039 vs. responders week 52, ‡P = 0.793 vs. nonresponders week 52, and §P = 0.092 vs. nonresponders week 52. D: *P = 0.025 vs. nonresponders at week 13, †P = 0.947 vs. responders week 52, ‡P = 0.021 vs. nonresponders week 52, and §P = 0.001 vs. nonresponders week 52. Data are means ± SEM.
Figure 4 β-Cell function after anakinra withdrawal. β-Cell function assessed by PI/I (A); and AUC for C-peptide during an oral glucose-tolerance test (B); an intravenous stimulation with glucose, glucagon, and arginine (C); and the oral and intravenous test combined (D) at baseline, anakinra withdrawal (week 13), and end of study (week 52) in patients with (□, responders) or without (■, nonresponders) any reduction in A1C after 13 weeks of anakinra treatment. A: *P = 0.041 vs. nonresponders at week 13, †P = 0.435 vs. responders week 52, ‡P = 0.016 vs. nonresponders week 52, and §P = 0.005 vs. nonresponders week 52. B: *P = 0.006 vs. nonresponders at week 13, †P = 0.750 vs. responders week 52, ‡P = 0.021 vs. nonresponders week 52, and §P = 0.008 vs. nonresponders week 52. C: *P = 0.048 vs. nonresponders at week 13, †P = 0.039 vs. responders week 52, ‡P = 0.793 vs. nonresponders week 52, and §P = 0.092 vs. nonresponders week 52. D: *P = 0.025 vs. nonresponders at week 13, †P = 0.947 vs. responders week 52, ‡P = 0.021 vs. nonresponders week 52, and §P = 0.001 vs. nonresponders week 52. Data are means ± SEM.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

Items 301–400 of 407

Metadata

Authors
Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T.
Affiliations
  • Hagedorn Research Institute and Steno Diabetes Center, Gentofte, Denmark;
  • University Hospital Zurich (CH)
  • Lund University (SE)
  • University of Copenhagen (DK)
Corresponding author
Mandrup-Poulsen, Thomas
Venue
Diabetes Care
Published
2009-06-19
Volume
32
Issue
9
Pages
1663-1668
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2137334382
Cited by
401
References
28
Citations by year
2026: 5 · 2025: 8 · 2024: 27 · 2023: 15 · 2022: 14 · 2021: 28 · 2020: 16 · 2019: 21 · 2018: 11 · 2017: 23 · 2016: 21 · 2015: 27 · 2014: 36 · 2013: 42 · 2012: 32
FWCI
35.76
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
  • Lund University Publications (Lund University) (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
interleukin-1 receptor antagonist, anakinra, type 2 diabetes, beta-cell function, insulin secretion, beta-cell apoptosis, IL-1 blockade, C-peptide, proinsulin/insulin ratio, C-reactive protein, interleukin-6, systemic inflammation, treatment withdrawal, glycemic control
MeSH terms
Diabetes Mellitus, Type 2, Female, Humans, Male, Antirheumatic Agents, Insulin-Secreting Cells, Interleukin 1 Receptor Antagonist Protein, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.